References
- Bohle A, Muller GA, Wehrmann W, et al. Pathogenesis of chronic renal failure in the primary glomerulopathies, renal vasculopathies, and chronic interstitial nephritides. Kidney Int Suppl 1996 May; 54: S2–9
- Ruiz-Torres MP, Bosch RJ, O'Valle F, et al. Age-related increase in expression of TGF-ß1 in the rat kidney: relationship to morphologic changes. J Am Soc Nephrol 1998; 9(5): 782–91
- Paul LC. Chronic allograft nephropathy: an update. Kidney Int 1999; 56(3): 783–93
- Norman JT, Fine LG. Progressive renal disease: fibroblasts, extracellular matrix, and integrins. Exp Nephrol 1999; 7(2): 167–77
- Rodemann HP, Muller GA. Characterization of human renal fibroblast in health and disease: part II. In vitro growth, differentiation, and collagen synthesis of fibroblasts from kidneys with interstitial fibrosis. Am J Kidney Dis 1991; 17(6): 684–6
- Healy E, Leonard M, Madrigal-Estebas L, et al. Factors produced by activated leukocytes alter renal epithelial cell differentiation. Kidney Int 1999; 56(4): 1266–9
- Fan JM, Ng YY, Hill PA, et al. Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int 1999; 56(4): 1455–67
- Johnson DW, Saunders HJ, Baxter RC, et al. Paracrine stimulation of human renal fibroblasts by proximal tubule cells. Kidney Int 1998; 54(3): 747–57
- Ando T, Okuda S, Yanagida T, et al. Localization of TGF-beta and its receptors in the kidney. Miner Electrolyte Metab 1998; 24(2–3): 149–53
- Roberts AB. Molecular and cell biology of TGF-beta. Miner Electrolyte Metab 1998; 24(2–3): 111–9
- Frishberg Y, Kelly CJ. TGF-beta and regulation of interstitial nephritis. Miner Electrolyte Metab 1998; 24(2–3): 181–9
- Suthanthiran M, Khanna A, Cukran D, et al. Transforming growth factor-beta, hyperexpression in African American end-stage renal disease patients. Kidney Int 1998; 53(3): 639–44
- Cohen AH, Nast CC. TGF-beta in renal allograft rejection. Miner Electrolyte Metab 1998; 24(2–3): 197–201
- Cuhaci B, Kumar MS, Bloom RD, et al. Transforming growth factor-beta levels in human allograft chronic fibrosis correlate with rate of decline in renal function. Transplantation 1999; 68(6): 785–90
- Matsusaka T, Hymes J, Ichikawa I. Angiotensin in progressive renal diseases: theory and practice. J Am Soc Nephrol 1996; 7(10): 2025–43
- Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334(15): 939–45
- Noda M, Matsuo T, Fukuda R, et al. Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure. Kidney Int 1999; 56(3): 898–909
- Johnson RJ, Alpers CE, Yoshimura A, et al. Renal injury from angiotensin II-mediated hypertension. Hypertension 1992; 19(5): 464–74
- Wolf G, Neilson EG. Angiotensin II as a hypertrophogenic cytokine for proximal tubular cells. Kidney Int Suppl 1993; 39:S 100–7
- Ruiz-Ortega M, Egido J. Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int 1997; 52(6):1497–1510
- Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 1998; 31(1 Pt 2): 181–8
- Klahr S, Morrissey JJ. Comparative study of ACE inhibitors and angiotensin II receptor antagonists in interstitial scarring. Kidney Int Suppl 1997; 63:S111–4
- Sharma K, Eltayeb BO, McGowan TA, et al. Captopril- induced reduction of serum levels of transforming growth factor- beta 1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 1999; 34(5): 818–23
- Peters H, Border WA, Noble N. Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998; 54(5): 1570–80
- Iyer SN, Wild JS, Schiedt MJ, et al. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med 1995; 125(6): 779–85
- Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone. Am J Respir Crit Care Med 1999; 159(4Pt l):1061–9
- Fukagawa M, Noda M, Shimizu T, et al. Chronic progressive interstitial fibrosis in renal disease: are there novel pharmacological approaches? Nephrol Dial Transplant 1999; 14(12): 2793–5
- Sharpe CC, Dockrell ME, Scott R, et al. Evidence of a role for Ki-Ras in the stimulated proliferation of renal fibroblasts. J Am Soc Nephrol 1999; 10(6): 1186–92
- Tamanoi F. Inhibitors of Ras farnesyltransferases. Trends Biochem Sci 1993; 18(9): 349–53
- Oda H, Keane WF. Recent advances in statins and the kidney. Kidney Int Suppl 1999; 71:S2–5